Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...
The Europe-wide approval is the first ever insulin treatment licensed through the European Medicines Agency's biosimilar pathway, and the fourth diabetes product approved in the EU from the Lilly ...
28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback